Literature DB >> 17471238

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

M M Moasser1.   

Abstract

The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer. This finding established the HER2 oncogene hypothesis for the development of some human cancers. The subsequent two decades have brought about an explosion of information about the biology of HER2 and the HER family. An abundance of experimental evidence now solidly supports the HER2 oncogene hypothesis and etiologically links amplification of the HER2 gene locus with human cancer pathogenesis. The molecular mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged. Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by experimental models and HER2 may indeed induce cell transformation through multiple mechanisms. Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the experimental evidence with human cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471238      PMCID: PMC3021475          DOI: 10.1038/sj.onc.1210477

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  223 in total

1.  The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years.

Authors:  Karen G Montgomery; Dorota M Gertig; Simon W Baxter; Roger L Milne; Gillian S Dite; Margaret R E McCredie; Graham G Giles; Melissa C Southey; John L Hopper; Ian G Campbell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

2.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

3.  Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.

Authors:  L T Amundadottir; P Leder
Journal:  Oncogene       Date:  1998-02-12       Impact factor: 9.867

4.  Role of exon-16-deleted HER2 in breast carcinomas.

Authors:  F Castiglioni; E Tagliabue; M Campiglio; S M Pupa; A Balsari; S Ménard
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

5.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

Authors:  Carl Morrison; Vanna Zanagnolo; Nilsa Ramirez; David E Cohn; Nicole Kelbick; Larry Copeland; G Larry Maxwell; Larry G Maxwell; Jeffrey M Fowler
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.

Authors:  Bart S Hendriks; H Steven Wiley; Douglas Lauffenburger
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

7.  Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7.

Authors:  Maya Shelly; Yaron Mosesson; Ami Citri; Sara Lavi; Yaara Zwang; Naomi Melamed-Book; Benjamin Aroeti; Yosef Yarden
Journal:  Dev Cell       Date:  2003-09       Impact factor: 12.270

Review 8.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

Authors:  Jeffrey S Ross; Jonathan A Fletcher; Gerald P Linette; James Stec; Edward Clark; Mark Ayers; W Fraser Symmans; Lajos Pusztai; Kenneth J Bloom
Journal:  Oncologist       Date:  2003

9.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

10.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.

Authors:  Mitchell B Berger; Jeannine M Mendrola; Mark A Lemmon
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

View more
  353 in total

1.  Trastuzumab.

Authors:  Annelies H Boekhout; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients.

Authors:  Jun-Te Hsu; Tse-Ching Chen; Jeng-Hwei Tseng; Cheng-Tang Chiu; Keng-Hao Liu; Chun-Nan Yeh; Tsann-Long Hwang; Yi-Yin Jan; Ta-Sen Yeh
Journal:  Oncologist       Date:  2011-12-05

3.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

4.  Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.

Authors:  Goldi A Kozloski; Coralie A Carothers Carraway; Kermit L Carraway
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

Review 5.  Molecular imaging-its current role in cancer.

Authors:  S McDermott; A Kilcoyne
Journal:  QJM       Date:  2015-08-07

6.  Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.

Authors:  Tyler Risom; Xiaoyan Wang; Juan Liang; Xiaoli Zhang; Carl Pelz; Lydia G Campbell; Jenny Eng; Koei Chin; Caroline Farrington; Goutham Narla; Ellen M Langer; Xiao-Xin Sun; Yulong Su; Colin J Daniel; Mu-Shui Dai; Christiane V Löhr; Rosalie C Sears
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

7.  S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling.

Authors:  Chengshan Xu; Hongyan Chen; Xiang Wang; Jidong Gao; Yiqun Che; Yi Li; Fang Ding; Aiping Luo; Shuguang Zhang; Zhihua Liu
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

8.  Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy.

Authors:  Christian Cadeddu; Alessandra Piras; Mariele Dessì; Clelia Madeddu; Giovanni Mantovani; Mario Scartozzi; Andreas Hagendorff; Paolo Colonna; Giuseppe Mercuro
Journal:  Int J Cardiovasc Imaging       Date:  2016-10-01       Impact factor: 2.357

9.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 10.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors:  Natalia V Sergina; Mark M Moasser
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.